AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 917399 — intervention group
Group type: EXPERIMENTAL
Intervention: Food supplementation and/or psychological stimulation
Number of subjects: 456
Study 917399 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 456
Study 31788775 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position (P)
Number of subjects: 51
Study 31788775 — intervention group
Group type: COMPARATOR
Intervention: Lateral position (L)
Number of subjects: 51
Study 31451978 — intervention group
Group type: COMPARATOR
Intervention: Internet-based cognitive behavioral therapy (iCBT) with therapist support
Number of subjects: 0
Study 31451978 — intervention group
Group type: COMPARATOR
Intervention: Internet-based cognitive behavioral therapy (iCBT) without therapist support
Number of subjects: 0
Study 31451978 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 0
Study 28643064 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-expandable metallic stent (SEMS) placement combined with intraluminal 125I seed strands brachytherapy
Number of subjects: 0
Study 28643064 — intervention group
Group type: COMPARATOR
Intervention: Self-expandable metallic stent (SEMS) without brachytherapy
Number of subjects: 0
Study 25876640 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil group (S) - 150 mL normal saline containing 2.5 µg/kg sufentanil citrate and 6 mg tropisetron for 48 hours
Number of subjects: 60
Study 25876640 — intervention group
Group type: EXPERIMENTAL
Intervention: Dezocine+sufentanil group (DS) - 150 mL normal saline containing 0.25 mg/kg dezocine, 1.5 µg/kg sufentanil citrate, and 6 mg tropisetron for 48 hours
Number of subjects: 60
Study 25876640 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil group (S)
Number of subjects: 60
Study 25876640 — intervention group
Group type: EXPERIMENTAL
Intervention: Dezocine+sufentanil group (DS)
Number of subjects: 60
Study 24158983 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse practitioner support added to physician care
Number of subjects: 788
Study 24158983 — intervention group
Group type: COMPARATOR
Intervention: Physician care alone
Number of subjects: 788
Study 21103921 — intervention group
Group type: EXPERIMENTAL
Intervention: Lycopene (30 mg/day)
Number of subjects: 69
Study 21103921 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (3 g/day, including 1,098 mg eicosapentaenoic and 549 mg docosahexaenoic fatty acids)
Number of subjects: 69
Study 21103921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 19019930 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue (FG) (Tisseel)
Number of subjects: 40
Study 19019930 — intervention group
Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 40
Study 17400317 — intervention group
Group type: EXPERIMENTAL
Intervention: Contemplation condition
Number of subjects: 0
Study 17400317 — intervention group
Group type: COMPARATOR
Intervention: Viewing condition
Number of subjects: 0
Study 15257186 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide SR 1.5 mg
Number of subjects: 570
Study 15257186 — intervention group
Group type: COMPARATOR
Intervention: Enalapril 10 mg
Number of subjects: 570
Study 15257186 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide SR
Number of subjects: 570
Study 15257186 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 570
Study 11606671 — intervention group
Group type: EXPERIMENTAL
Intervention: PVP+PVS (unilateral GPi lesion plus contralateral GPi stimulation)
Number of subjects: 6
Study 11606671 — intervention group
Group type: COMPARATOR
Intervention: Bilateral PVP (simultaneous bilateral GPi lesion)
Number of subjects: 6
Study 9583541 — intervention group
Group type: EXPERIMENTAL
Intervention: End-inspiratory pause (EIP) at 0%
Number of subjects: 11
Study 9583541 — intervention group
Group type: EXPERIMENTAL
Intervention: End-inspiratory pause (EIP) at 10%
Number of subjects: 11
Study 9583541 — intervention group
Group type: EXPERIMENTAL
Intervention: End-inspiratory pause (EIP) at 30%
Number of subjects: 11
Study 9583541 — intervention group
Group type: EXPERIMENTAL
Intervention: End-inspiratory pause (EIP) at varying durations (0%, 10%, 30%)
Number of subjects: 11
Study 8018682 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive computer software intervention
Number of subjects: 368
Study 8018682 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 368
Study 31615937 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib alone
Number of subjects: 100
Study 31615937 — intervention group
Group type: EXPERIMENTAL
Intervention: Abemaciclib plus anastrozole
Number of subjects: 100
Study 31615937 — intervention group
Group type: COMPARATOR
Intervention: Anastrozole alone
Number of subjects: 100
Study 31615937 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Abemaciclib + Anastrozole)
Number of subjects: 100
Study 31615937 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (Abemaciclib, Anastrozole, Combination)
Number of subjects: 100
Study 29210828 — intervention group
Group type: EXPERIMENTAL
Intervention: MC lenses (MiSight or Proclear Multifocal-Distance +2.00D)
Number of subjects: 43
Study 29210828 — intervention group
Group type: COMPARATOR
Intervention: SV lenses (1-DAY ACUVUE MOIST)
Number of subjects: 43
Study 27113948 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral TXA (1.95g orally 2 hours preoperatively)
Number of subjects: 71
Study 27113948 — intervention group
Group type: COMPARATOR
Intervention: IV TXA (1g IV bolus before wound closure)
Number of subjects: 71
Study 24690201 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive treatment (clinician controlled), receiving care on a regular basis
Number of subjects: 400
Study 24690201 — intervention group
Group type: COMPARATOR
Intervention: Symptom-guided treatment (patient controlled), receiving care when patients feel a need
Number of subjects: 400
Study 24690201 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive treatment (clinician controlled)
Number of subjects: 400
Study 24690201 — intervention group
Group type: COMPARATOR
Intervention: Symptom-guided treatment (patient controlled)
Number of subjects: 400
Study 21744032 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild Alzheimer's disease (AD)
Number of subjects: 100
Study 21744032 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Alzheimer's disease (AD)
Number of subjects: 100
Study 21744032 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe Alzheimer's disease (AD)
Number of subjects: 100
Study 20305098 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol
Number of subjects: 44
Study 20305098 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol
Number of subjects: 44
Study 18607963 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic gentamicin treatment
Number of subjects: 0
Study 16322468 — intervention group
Group type: EXPERIMENTAL
Intervention: Total therapy 2 without thalidomide (TT2)
Number of subjects: 345
Study 16322468 — intervention group
Group type: COMPARATOR
Intervention: Total therapy 1 (TT1)
Number of subjects: 345
Study 12936973 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid 600 mg single oral dose
Number of subjects: 24
Study 10867849 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal CPAP
Number of subjects: 150
Study 8781902 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic variceal band ligation (EVL)
Number of subjects: 68
Study 8781902 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 68
Study 1622642 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg daily for 2 years
Number of subjects: 2000
Study 1622642 — intervention group
Group type: COMPARATOR
Intervention: Perioperative cyclophosphamide
Number of subjects: 2000
Study 1622642 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 2000
Study 6372563 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril and furosemide
Number of subjects: 2
Study 6372563 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 2
Study 6372563 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril followed by furosemide
Number of subjects: 2
Study 30368338 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Neuromuscular Inhibition Technique (INIT)
Number of subjects: 32
Study 30368338 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 32
Study 27546745 — intervention group
Group type: COMPARATOR
Intervention: suture + BPU (control)
Number of subjects: 221
Study 24502830 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine 5.25 mg/kg
Number of subjects: 616
Study 24502830 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine 3.5 mg/kg
Number of subjects: 616
Study 24502830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 616
Study 21499876 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates exercise program (1 hour, 3 times a week for 12 weeks)
Number of subjects: 55
Study 21499876 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment programs (control group)
Number of subjects: 55
Study 21499876 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates exercise program
Number of subjects: 55
Study 20007923 — intervention group
Group type: EXPERIMENTAL
Intervention: BIBW 2948 (15 mg twice a day)
Number of subjects: 48
Study 20007923 — intervention group
Group type: EXPERIMENTAL
Intervention: BIBW 2948 (30 mg twice a day)
Number of subjects: 48
Study 20007923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 18673350 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen and diphenhydramine
Number of subjects: 315
Study 18673350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study 15910627 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes
Number of subjects: 267
Study 15910627 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-treated Type 2 diabetes
Number of subjects: 267
Study 12632426 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin plus low-dose aspirin
Number of subjects: 40
Study 12632426 — intervention group
Group type: COMPARATOR
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 40
Study 10528065 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally laparoscopic aortic surgery (both transperitoneal and retroperitoneal approaches)
Number of subjects: 0
Study 10528065 — intervention group
Group type: COMPARATOR
Intervention: Open vascular surgery
Number of subjects: 0
Study 8785254 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin in combination with isoniazid, ethambutol, and clofazimine
Number of subjects: 50
Study 8785254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 8785254 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin in multidrug regimens
Number of subjects: 50
Study 1718367 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplements (30 mg/d for 3 d)
Number of subjects: 30
Study 1718367 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 30
Study 6355046 — intervention group
Group type: EXPERIMENTAL
Intervention: vidarabine
Number of subjects: 0
Study 6355046 — intervention group
Group type: COMPARATOR
Intervention: acyclovir
Number of subjects: 0
Study 28986029 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily regimen
Number of subjects: 191
Study 28986029 — intervention group
Group type: COMPARATOR
Intervention: Time-driven regimen
Number of subjects: 191
Study 28986029 — intervention group
Group type: COMPARATOR
Intervention: Event-driven regimen
Number of subjects: 191
Study 27157292 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-day discharge (SD), n = 50
Number of subjects: 493
Study 27157292 — intervention group
Group type: COMPARATOR
Intervention: Delayed discharge (DD), n = 50
Number of subjects: 493
Study 27157292 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-day discharge (SD)
Number of subjects: 493
Study 27157292 — intervention group
Group type: COMPARATOR
Intervention: Delayed discharge (DD)
Number of subjects: 493
Study 25127090 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous hydrocortisone infusion (CSHI)
Number of subjects: 10
Study 25127090 — intervention group
Group type: COMPARATOR
Intervention: Oral hydrocortisone
Number of subjects: 10
Study 25127090 — intervention group
Group type: EXPERIMENTAL
Intervention: CSHI
Number of subjects: 10
Study 22978561 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First intervention (Assertive Community Treatment for high needs participants and Intensive Case Management for moderate needs participants)
Number of subjects: 575
Study 22978561 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (control)
Number of subjects: 575
Study 20520291 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment at 2 weeks
Number of subjects: 299
Study 20520291 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment at 4 weeks
Number of subjects: 299
Study 20520291 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment at 6 weeks
Number of subjects: 299
Study 18031315 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (7.5 mg/day) added to flutamide (62.5 mg/day) and metformin (850 mg/day)
Number of subjects: 38
Study 18031315 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 38
Study 15919695 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily haemodialysis (DHD) - 2-3 hours, 6 times/week
Number of subjects: 37
Study 15919695 — intervention group
Group type: COMPARATOR
Intervention: Standard haemodialysis (SHD) - 4-5 hours, 3 times/week
Number of subjects: 37
Study 15919695 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 37
Study 15919695 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily haemodialysis (DHD)
Number of subjects: 37
Study 15919695 — intervention group
Group type: COMPARATOR
Intervention: Standard haemodialysis (SHD)
Number of subjects: 37
Study 12640217 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine
Number of subjects: 44
Study 12640217 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 44
Study 11471639 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of etodolac
Number of subjects: 36
Study 11471639 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg of ibuprofen
Number of subjects: 36
Study 11471639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 9094887 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acid (PUFA) ingestion (0.1:1 and 0.5:1 ratios to n-6 PUFAs) for 1 month each
Number of subjects: 0
Study 9094887 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acid (PUFA) ingestion (low dosage)
Number of subjects: 0
Study 9094887 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acid (PUFA) ingestion (high dosage)
Number of subjects: 0
Study 8104091 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg IV bolus of etilefrine followed by continuous infusion (0.35 mg.kg‐1.h‐1)
Number of subjects: 148
Study 8104091 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 ml.kg‐1 infusion of saline isotonic solution for 90 min
Number of subjects: 148
Study 8104091 — intervention group
Group type: COMPARATOR
Intervention: No preventive treatment (control group)
Number of subjects: 148
Study 2883784 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP vaccine, initial immunization at five months of age or later, second dose at eight weeks or more
Number of subjects: 0
Study 2883784 — intervention group
Group type: COMPARATOR
Intervention: DTP vaccine, initial immunization at ages less than five months
Number of subjects: 0
Study 31323295 — intervention group
Group type: EXPERIMENTAL
Intervention: Soccer training + caloric-restricted diet (SDG)
Number of subjects: 51
Study 31323295 — intervention group
Group type: COMPARATOR
Intervention: Caloric-restricted diet alone (DG)
Number of subjects: 51
Study 30273901 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone self-help application (Be Good to Yourself) for four weeks
Number of subjects: 90
Study 30273901 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone self-help application (Be Good to Yourself) for frequent users
Number of subjects: 90
Study 30273901 — intervention group
Group type: COMPARATOR
Intervention: Wait-list group (control)
Number of subjects: 90
Study 30273901 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone self-help application (Be Good to Yourself)
Number of subjects: 90
Study 26337853 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional facial expressions identification task using virtual emotional faces
Number of subjects: 107
Study 24630820 — intervention group
Group type: EXPERIMENTAL
Intervention: Burn rehabilitation massage therapy
Number of subjects: 146
Study 24630820 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation therapy for hypertrophic scars
Number of subjects: 146
Study 22471132 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine 1 mg orally, twice a day + electroacupuncture (Baihui, Sishengcong, Yintang) once a day
Number of subjects: 60
Study 22471132 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine 2 mg orally, twice a day
Number of subjects: 60
Study 19825835 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening administered bimatoprost/timolol fixed combination (BTFC)
Number of subjects: 60
Study 19825835 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning administered bimatoprost/timolol fixed combination (BTFC)
Number of subjects: 60
Study 19825835 — intervention group
Group type: COMPARATOR
Intervention: Bimatoprost monotherapy
Number of subjects: 60
Study 19825835 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening BTFC
Number of subjects: 60
Study 19825835 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning BTFC
Number of subjects: 60
Study 17661244 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-lifting sign
Number of subjects: 239
Study 17661244 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic assessment
Number of subjects: 239
Study 15692986 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam 0.125 mg/kg body weight (single daily dose)
Number of subjects: 225
Study 15692986 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam 0.25 mg/kg body weight (single daily dose)
Number of subjects: 225
Study 15692986 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 10 mg/kg body weight (2 daily doses)
Number of subjects: 225
Study 12685513 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg/day
Number of subjects: 133
Study 12685513 — intervention group
Group type: COMPARATOR
Intervention: Nicardipine 60 mg/day (titrated to 10 mg/day if necessary)
Number of subjects: 133
Study 10327211 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellular and cytokine therapy
Number of subjects: 0
Study 10327211 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy
Number of subjects: 0
Study 7720349 — intervention group
Group type: EXPERIMENTAL
Intervention: Five small hourly meals
Number of subjects: 12
Study 7720349 — intervention group
Group type: EXPERIMENTAL
Intervention: Single larger meal
Number of subjects: 12
Study 7720349 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeding (both meal regimens)
Number of subjects: 12
Study 1904620 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 61
Study 1904620 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine
Number of subjects: 61
Study 7188111 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (400 mg X 3/day/4 weeks p.o.)
Number of subjects: 20
Study 7188111 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 31472669 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 60 mg.kg-1
Number of subjects: 45
Study 31472669 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 45
Study 28157825 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia before cervical punch biopsy
Number of subjects: 204
Study 28157825 — intervention group
Group type: COMPARATOR
Intervention: Cervical punch biopsy without local anesthesia
Number of subjects: 204
Study 28157825 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia during biopsy
Number of subjects: 204
Study 28157825 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of local anesthetic
Number of subjects: 204
Study 25971958 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative infection prevention bundle
Number of subjects: 163
Study 25971958 — intervention group
Group type: COMPARATOR
Intervention: Standard infection prophylaxis
Number of subjects: 163
Study 25382769 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition consultation (PwH-I)
Number of subjects: 38
Study 25382769 — intervention group
Group type: COMPARATOR
Intervention: No intervention (PwH-O)
Number of subjects: 38
Study 22305829 — intervention group
Group type: EXPERIMENTAL
Intervention: TAXUS Liberté stent with concomitant prasugrel therapy (1 year)
Number of subjects: 4200
Study 22305829 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel plus aspirin (1 year)
Number of subjects: 4200
Study 22305829 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (5 and 10 mg daily doses)
Number of subjects: 4200
Study 22305829 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (12 versus 30 months)
Number of subjects: 4200
Study 21163755 — intervention group
Group type: EXPERIMENTAL
Intervention: DD-I (patients before treatment)
Number of subjects: 30
Study 21163755 — intervention group
Group type: EXPERIMENTAL
Intervention: DD-II (patients after 8 weeks of pharmacological treatment)
Number of subjects: 30
Study 21163755 — intervention group
Group type: COMPARATOR
Intervention: CG (control group)
Number of subjects: 30
Study 17878470 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 16319260 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose
Number of subjects: 90
Study 16319260 — intervention group
Group type: COMPARATOR
Intervention: Oral iron polymaltose complex (300 mg elemental iron per day)
Number of subjects: 90
Study 12411535 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants (AOX) ascorbic acid (2 g, I.V.) and alpha‐tocopherol (200 mg, P.O.)
Number of subjects: 16